Jefferies upgrades Zydus Life to 'Buy' on strong US pipeline potential, stock up 4%

Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a 'Buy' rating, citing the strength of the company’s US pipeline as a major growth driver. Jefferies raised its target price to Rs 1,450 from Rs 1,210, indicating a 30% upside from the previous closing price of Rs 1,113.80.